TherapeuticsMD and TPG Sixth Street Partners have amended the terms of the company’s existing term loan financing facility to revise the draw trigger for one of the two $50 million delayed draw loan tranches thereunder.

The terms of the amendment no longer require that ANNOVERA be designated as a new category of birth control by the U.S. Food and Drug Administration for the company to draw the loan tranche. As amended, the $50 million loan tranche may be made available to the company at Sixth Street’s sole and absolute discretion either contemporaneously with the delivery of the company’s financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as Sixth Street may consent to.

All other terms and conditions of the facility remain in full force and effect, including the conditions for the company to draw the other $50 million loan tranche thereunder upon the company achieving $11 million in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019.

“We are pleased that our lenders continue to be supportive and demonstrate confidence in our business as we progress toward the full commercial launch of ANNOVERA in the first quarter of 2020,” said Robert G. Finizio, CEO of TherapeuticsMD.

TherapeuticsMD is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women..

TPG Sixth Street Partners is a global finance and investment business with more than $33 billion in assets under management.